Intervention not reported
2c. Adequate immune response (seroprotection) against pertussis (not measured) · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
2d. Adequate immune response (seroprotection) against Haemophilus influenzae type b disease (surrogate outcome) · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
The intervention probably leads to higher 2d. Adequate immune response (seroprotection) against Haemophilus… (moderate certainty).
1 finding from 1 review
Intervention not reported
Pain (not measured) · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
4b. Persistent inconsolable crying4 · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
It is very uncertain whether the intervention changes 4b. Persistent inconsolable crying4 (very low certainty).
1 finding from 1 review
Intervention not reported
Severe local reaction8 · infants aged approximately 2 to 6 months undergoing vaccination in the anterolateral thigh with a DTwP‐Hib vaccine
The intervention probably leads to lower severe local reaction8 (moderate certainty).
1 finding from 1 review
Neonatal death due to pneumococcal infection · Pregnant women undergoing vaccination to prevent infant infection
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Neonatal infection ‐ Pneumonia · Pregnant women undergoing vaccination to prevent infant infection
Pneumococcal vaccine showed no clear difference in neonatal infection ‐ Pneumonia compared with control vaccine (low certainty).
1 finding from 1 review
Neonatal infection ‐ Meningitis · Pregnant women undergoing vaccination to prevent infant infection
Pneumococcal vaccine showed no clear difference in neonatal infection ‐ Meningitis compared with control vaccine (low certainty).
1 finding from 1 review
Neonatal infection ‐ Otitis media · Pregnant women undergoing vaccination to prevent infant infection
Pneumococcal vaccine showed no clear difference in neonatal infection ‐ Otitis media compared with control vaccine (low certainty).
1 finding from 1 review
Neonatal infection · Pregnant women undergoing vaccination to prevent infant infection
Pneumococcal vaccine showed no clear difference in neonatal infection ‐ All infections compared with control vaccine (low certainty).
1 finding from 1 review
Pneumococcal colonization ‐ At 2‐3 months of age · Pregnant women undergoing vaccination to prevent infant infection
Pneumococcal vaccine showed no clear difference in pneumococcal colonization ‐ At 2‐3 months of age compared with control vaccine (low certainty).
1 finding from 1 review
Pneumococcal colonization ‐ By 6‐7 months of age · Pregnant women undergoing vaccination to prevent infant infection
Pneumococcal vaccine showed no clear difference in pneumococcal colonization ‐ By 6‐7 months of age compared with control vaccine (low certainty).
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in clinical improvement: discharged alive ( compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Hospital‐acquired infections ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Invasive fungal infection · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review